After Today’s Huge Increase, Is AMAG Pharmaceuticals, Inc. (AMAG)’s Near-Term Analysis Positive?

February 15, 2018 - By Winifred Garcia

Investors sentiment increased to 1.44 in Q3 2017. Its up 0.35, from 1.09 in 2017Q2. It increased, as 21 investors sold AMAG Pharmaceuticals, Inc. shares while 43 reduced holdings. 35 funds opened positions while 57 raised stakes. 39.98 million shares or 4.47% less from 41.85 million shares in 2017Q2 were reported.
Dupont Cap Mgmt Corporation has 0.01% invested in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). State Teachers Retirement reported 15,025 shares. Lsv Asset Management stated it has 0.05% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Metropolitan Life Insur Ny stated it has 0% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Jpmorgan Chase And Co reported 546,166 shares stake. Falcon Point Cap Lc owns 839,477 shares for 1.91% of their portfolio. Schwab Charles Invest Inc invested 0.01% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Prudential Fincl has invested 0.02% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Employees Retirement Of Texas, Texas-based fund reported 48,000 shares. Bank Of America De has invested 0% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Wisconsin-based State Of Wisconsin Board has invested 0% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Credit Suisse Ag invested in 50,748 shares or 0% of the stock. Barclays Public Ltd Liability accumulated 5,532 shares. Trexquant L P invested 0.1% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). 185,762 were accumulated by Ameriprise Financial.

Since August 29, 2017, it had 0 insider purchases, and 1 sale for $20,938 activity.

The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) is a huge mover today! The stock increased 27.70% or $3.85 during the last trading session, reaching $17.75. About 8.95 million shares traded or 968.59% up from the average. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has risen 3.00% since February 15, 2017 and is uptrending. It has underperformed by 13.70% the S&P500.
The move comes after 7 months positive chart setup for the $627.89 million company. It was reported on Feb, 15 by Barchart.com. We have $18.28 PT which if reached, will make NASDAQ:AMAG worth $18.84 million more.

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Ratings Coverage

Among 14 analysts covering AMAG Pharmaceuticals (NASDAQ:AMAG), 4 have Buy rating, 1 Sell and 9 Hold. Therefore 29% are positive. AMAG Pharmaceuticals had 38 analyst reports since August 18, 2015 according to SRatingsIntel. The firm earned “Outperform” rating on Wednesday, May 4 by Leerink Swann. The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has “Hold” rating given on Monday, July 24 by Cantor Fitzgerald. Deutsche Bank maintained it with “Hold” rating and $50 target in Wednesday, November 4 report. As per Monday, January 9, the company rating was downgraded by Raymond James. Raymond James initiated AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) on Tuesday, September 1 with “Outperform” rating. Jefferies maintained it with “Buy” rating and $16.0 target in Friday, November 3 report. The company was downgraded on Tuesday, January 10 by Leerink Swann. Zacks downgraded the shares of AMAG in report on Wednesday, August 19 to “Strong-Buy” rating. The stock has “Hold” rating by Deutsche Bank on Thursday, September 3. The firm has “Buy” rating by Jefferies given on Tuesday, June 6.

More notable recent AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) news were published by: Seekingalpha.com which released: “Your Daily Pharma Scoop: AMAG Gets Label Expansion For Feraheme, Bristol-Myers …” on February 06, 2018, also Marketwatch.com with their article: “Antares Pharma, Amag Pharma shares soar premarket after FDA approves auto injector” published on February 15, 2018, Seekingalpha.com published: “AMAG Pharmaceuticals Could Be February’s Breakout Biopharma Stock” on January 30, 2018. More interesting news about AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) were released by: Globenewswire.com and their article: “AMAG Pharmaceuticals Announces FDA Approval of Supplemental New Drug …” published on February 05, 2018 as well as Nasdaq.com‘s news article titled: “Commit To Purchase AMAG Pharmaceuticals At $12, Earn 43.9% Annualized Using …” with publication date: January 23, 2018.

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, makes, develops, and commercializes therapeutics for womenÂ’s health, anemia management, and cancer supportive care in the United States. The company has market cap of $627.89 million. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme , an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. It currently has negative earnings. The firm also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.